Peregrine Capital Management LLC Acquires 2,656 Shares of Azenta, Inc. $AZTA

Peregrine Capital Management LLC grew its holdings in Azenta, Inc. (NASDAQ:AZTA) by 1.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 157,126 shares of the company’s stock after acquiring an additional 2,656 shares during the quarter. Peregrine Capital Management LLC owned 0.34% of Azenta worth $4,836,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of AZTA. Mechanics Financial Corp lifted its position in Azenta by 77.6% in the second quarter. Mechanics Financial Corp now owns 870 shares of the company’s stock worth $27,000 after purchasing an additional 380 shares during the period. Farther Finance Advisors LLC lifted its position in Azenta by 41.6% in the second quarter. Farther Finance Advisors LLC now owns 1,371 shares of the company’s stock worth $42,000 after purchasing an additional 403 shares during the period. CWM LLC lifted its position in Azenta by 113.5% in the second quarter. CWM LLC now owns 1,898 shares of the company’s stock worth $58,000 after purchasing an additional 1,009 shares during the period. State of Wyoming lifted its position in Azenta by 77.1% in the first quarter. State of Wyoming now owns 2,343 shares of the company’s stock worth $81,000 after purchasing an additional 1,020 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its position in Azenta by 13,184.2% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,524 shares of the company’s stock worth $87,000 after purchasing an additional 2,505 shares during the period. 99.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on AZTA shares. Stephens started coverage on Azenta in a research report on Tuesday, July 22nd. They issued an “equal weight” rating and a $35.00 target price for the company. Evercore ISI set a $33.00 target price on Azenta and gave the stock an “in-line” rating in a research report on Tuesday, August 5th. Raymond James Financial raised Azenta from a “market perform” rating to an “outperform” rating and set a $35.00 target price for the company in a research report on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Azenta in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $35.75.

Azenta Stock Performance

Shares of NASDAQ AZTA opened at $31.36 on Wednesday. The stock has a market cap of $1.44 billion, a PE ratio of -12.96 and a beta of 1.62. The business has a fifty day moving average of $30.63 and a two-hundred day moving average of $29.79. Azenta, Inc. has a 52-week low of $23.91 and a 52-week high of $55.63.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The company had revenue of $143.94 million during the quarter, compared to analysts’ expectations of $149.64 million. Azenta had a positive return on equity of 1.35% and a negative net margin of 18.45%.The business’s revenue was up .0% on a year-over-year basis. During the same period last year, the business earned $0.14 earnings per share. Analysts predict that Azenta, Inc. will post 0.53 earnings per share for the current year.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.